Alexandra Teleki
Overview
Explore the profile of Alexandra Teleki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hempel N, Merkl P, Knopp M, Berthelsen R, Teleki A, Sotiriou G, et al.
Pharmaceutics
. 2021 Jul;
13(6).
PMID: 34205754
In this study, laser-induced in situ amorphization (i.e., amorphization inside the final dosage form) of the model drug celecoxib (CCX) with six different polymers was investigated. The drug-polymer combinations were...
12.
Hempel N, Merkl P, Asad S, Knopp M, Berthelsen R, Bergstrom C, et al.
Mol Pharm
. 2021 May;
18(6):2254-2262.
PMID: 33951909
Poor aqueous drug solubility represents a major challenge in oral drug delivery. A novel approach to overcome this challenge is drug amorphization inside a tablet, that is, on-demand drug amorphization....
13.
Johannesson J, Khan J, Hubert M, Teleki A, Bergstrom C
Int J Pharm
. 2021 Feb;
597:120304.
PMID: 33540029
Interest in 3D-printing technologies for pharmaceutical manufacturing of oral dosage forms is driven by the need for personalized medicines. Most research to date has focused on printing of polymeric-based drug...
14.
Asad S, Wegler C, Ahl D, Bergstrom C, Phillipson M, Artursson P, et al.
J Pharm Sci
. 2020 Nov;
110(1):239-250.
PMID: 33159915
Inflammatory bowel disease (IBD) is a chronic condition resulting in impaired intestinal homeostasis. Current practices for diagnosis of IBD are challenged by invasive, demanding procedures. We hypothesized that proteomics analysis...
15.
Teleki A, Nylander O, Bergstrom C
Pharmaceutics
. 2020 Jun;
12(6).
PMID: 32481718
The intrinsic dissolution rate (IDR) of active pharmaceutical ingredients (API) is a key property that aids in early drug development, especially selecting formulation strategies to improve dissolution and thereby drug...
16.
Bergstrom C, Box K, Holm R, Matthews W, McAllister M, Mullertz A, et al.
Eur J Pharm Biopharm
. 2019 Mar;
139:101-114.
PMID: 30862481
Intrinsic dissolution rate (IDR) is the surface specific dissolution rate of a drug. In early drug development, this property (among other parameters) is measured in order to compare different polymorphs...
17.
Alison L, Demirors A, Tervoort E, Teleki A, Vermant J, Studart A
Langmuir
. 2018 May;
34(21):6147-6160.
PMID: 29719151
In food-grade emulsions, particles with an appropriate surface modification can be used to replace surfactants and potentially enhance the stability of emulsions. During the life cycle of products based on...
18.
Plum J, Madsen C, Teleki A, Bevernage J, Mathews C, Karlsson E, et al.
Mol Pharm
. 2017 Oct;
14(12):4161-4169.
PMID: 29043811
The high number of poorly water-soluble compounds in drug development has increased the need for enabling formulations to improve oral bioavailability. One frequently applied approach is to induce supersaturation at...
19.
Adler C, Teleki A, Kuentz M
Int J Pharm
. 2017 Mar;
523(1):91-101.
PMID: 28286079
The formulation of lipophilic and hydrophobic compounds is a challenge for the pharmaceutical industry and it requires the development of complex formulations. Our first aim was to investigate hot-melt extrudate...
20.
Alison L, Ruhs P, Tervoort E, Teleki A, Zanini M, Isa L, et al.
Langmuir
. 2016 Dec;
32(50):13446-13457.
PMID: 27935304
Edible solid particles constitute an attractive alternative to surfactants as stabilizers of food-grade emulsions for products requiring a long-term shelf life. Here, we report on a new approach to stabilize...